Principal Securities Inc. Acquires 1,120 Shares of Insmed Incorporated (NASDAQ:INSM)

Principal Securities Inc. grew its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 55.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,139 shares of the biopharmaceutical company’s stock after buying an additional 1,120 shares during the quarter. Principal Securities Inc.’s holdings in Insmed were worth $217,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of INSM. V Square Quantitative Management LLC grew its stake in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in shares of Insmed during the fourth quarter valued at approximately $47,000. Blue Trust Inc. boosted its holdings in shares of Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Insmed in the third quarter valued at approximately $133,000. Finally, Avior Wealth Management LLC purchased a new stake in shares of Insmed in the fourth quarter valued at approximately $157,000.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sara Bonstein sold 18,322 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the sale, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. This trade represents a 13.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 532,207 shares of company stock worth $41,400,465 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Insmed Price Performance

Shares of INSM opened at $81.06 on Monday. The business’s 50-day moving average is $74.29 and its two-hundred day moving average is $73.61. The company has a market capitalization of $14.50 billion, a P/E ratio of -14.50 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

INSM has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday. Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday. Wells Fargo & Company increased their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Morgan Stanley increased their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $91.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.